Generate Biomedicines' Mike Nally on Thursday's $273M Series C and computational drug development

blonca9
Sep 18, 2023
1 min read

Mike Nally describes near term programs Generate is working on and how he sees computational advances changing where the field is headed over the longer term.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

Generate Biomedicines' Mike Nally on Thursday's $273M Series C and computational drug development

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight